中国真菌学杂志 2021, Vol. 16 Issue (3): 188-193,210.
黄志伟, 张菁
收稿日期:2020-12-24
出版日期:2021-06-28
发布日期:2021-06-28
通讯作者:
张菁,E-mail:zhangj_fudan@aliyun.com
E-mail:zhangj_fudan@aliyun.com
作者简介:黄志伟,男(汉族),博士研究生在读.E-mail:19111220041@fudan.edu.cn
Received:2020-12-24
Online:2021-06-28
Published:2021-06-28
中图分类号:
黄志伟, 张菁. 两性霉素B临床药理研究概述[J]. 中国真菌学杂志, 2021, 16(3): 188-193,210.
| [1] Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China[J]. Tumour Biol,2015,36(2):757-767. [2] Ostrosky-Zeichner L, Al-Obaidi M. Invasive fungal infections in the intensive care unit[J]. Infect Dis Clin North Am,2017,31(3):475-487. [3] von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection[J]. Dtsch Arztebl Int,2019,116(16):271-278. [4] Baginski M, Resat H, Borowski E. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels[J]. Biochim Biophys Acta,2002,1567(1-2):63-78. [5] Gray KC, Palacios D S, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol[J]. Proc Natl Acad Sci U S A,2012,109(7):2234-2239. [6] Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge[J]. Nat Chem Biol,2014,10(5):400-406. [7] Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs[J]. Clin Pharmacokinet,1983,8(1):17-42. [8] Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans[J]. Antimicrob Agents Chemother,2002,46(3):828-833. [9] Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate[J]. Antimicrob Agents Chemother,2002,46(3):834-840. [10] Ridente Y, Aubard J, Bolard J. Absence in amphotericin B-spiked human plasma of the free monomeric drug, as detected by SERS[J]. FEBS Lett,1999,446(2-3):283-286. [11] Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients[J]. Infection,2017,45(6):737-779. [12] Collette N, van der Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate[J]. Antimicrob Agents Chemother,1989,33(3):362-368. [13] Atkinson AJ, Bindschadler DD. Pharmacokinetics of intrathecally administered amphotericin B[J]. Am Rev Respir Dis,1969,99(6):917-924. [14] Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics[J]. Curr Clin Pharmacol,2007,2(1):37-58. [15] Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans[J]. Antimicrob Agents Chemother,1978,13(2):271-276. [16] Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds[J]. Infect Dis Clin North Am,2003,17(1):159-191. [17] Polak A. Pharmacokinetics of amphotericin B and flucytosine[J]. Postgrad Med J,1979,55(647):667-670. [18] Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal[J]. Pediatr Infect Dis J,1997,16(9):885-894. [19] Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, Part 3: Antivirals, antifungals, and urinary antiseptics[J]. J Hum Lact,2001,17(2):160-166. [20] Ilett KF, Kristensen JH. Drug use and breastfeeding[J]. Expert Opin Drug Saf,2005,4(4):745-768. [21] Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children[J]. Antimicrob Agents Chemother,1989,33(11):1989-1993. [22] Nath CE, Mclachlan AJ, Shaw PJ, et al. Amphotericin B dose optimization in children with malignant diseases[J]. Chemotherapy,2007,53(2):142-147. [23] Downes KJ, Fisher BT, Zane NR. Administration and dosing of systemic antifungal agents in pediatric patients[J]. Paediatr Drugs,2020,22(2):165-188. [24] Starke JR, Mason EJ, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children[J]. J Infect Dis,1987,155(4):766-774. [25] Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates[J]. J Pediatr,1990,116(5):791-797. [26] Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B[J]. J Infect Dis,1969,120(4):427-436. [27] Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion[J]. Antimicrob Agents Chemother,1985,27(5):868-871. [28] Block ER, Bennett J E, Livoti LG, et al. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man[J]. Ann Intern Med,1974,80(5):613-617. [29] Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis[J]. Am J Kidney Dis,2001,37(6):E45. [30] Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration[J]. J Antimicrob Chemother,2003,51(3):671-681. [31] Craven PC, Ludden TM, Drutz DJ, et al. Excretion pathways of amphotericin B[J]. J Infect Dis,1979,140(3):329-341. [32] Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature[J]. Clin Ther,2016,38(9):1976-1994. [33] Botero AJ, Restrepo HA. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function[J]. Cochrane Database Syst Rev,2015(11):D10481. [34] Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis[J]. Mycoses,2017,60(3):146-154. [35] Deray G. Amphotericin B nephrotoxicity[J]. J Antimicrob Chemother,2002,49 (Suppl 1):37-41. [36] Bullock WE, Luke RG, Nuttall CE, et al. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys[J]. Antimicrob Agents Chemother,1976,10(3):555-563. [37] Ellis ME, Al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B[J]. Antimicrob Agents Chemother,1992,36(1):172-179. [38] Hasnain MG, Nath P, Maruf S, et al. Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study[J]. BMC Res Notes,2018,11(1):918. [39] Meiring S, Fortuin-De SM, Kularatne R, et al. Prevalence and hospital management of amphotericin B deoxycholate-related toxicities during treatment of HIV-associated cryptococcal meningitis in South Africa[J]. PLoS Negl Trop Dis,2016,10(7):e4865. [40] Horwitz E, Shavit O, Shouval R, et al. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions[J]. Int J Clin Pharm,2012,34(4):611-617. [41] Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group[J]. N Engl J Med,1999,340(10):764-771. [42] Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group[J]. Am J Med,1989,86(6 Pt 1):668-672. [43] Ahimbisibwe C, Kwizera R, Ndyetukira JF, et al. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study[J]. BMC Infect Dis,2019,19(1):558. [44] Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis,2016,63(4):e1-e60. [45] Marra F, Partovi N, Wasan KM, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients[J]. Ann Pharmacother,2002,36(1):46-51. [46] Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients[J]. Transplantation,2003,75(9):1571-1574. [47] Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma[J]. Eur Respir J,1995,8(8):1263-1268. [48] Ho J, Fowler P, Heidari A, et al. Intrathecal amphotericin B: a 60-year experience in treating coccidioidal meningitis[J]. Clin Infect Dis,2017,64(4):519-524. [49] Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers[J]. J Infect Dis,1991,164(2):418-421. [50] Hoeprich PD. Elimination half-life of amphotericin B[J]. J Infect,1990,20(2):173-175. [51] Ayestaran A, Lopez RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia[J]. Antimicrob Agents Chemother,1996,40(3):609-612. [52] Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients[J]. Antimicrob Agents Chemother,1997,41(6):1275-1280. [53] Starke JR, Mason EJ, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children[J]. J Infect Dis,1987,155(4):766-774. [54] Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children[J]. J Pediatr,1988,113(3):559-563. [55] Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis[J]. Am J Kidney Dis,2001,37(6):E45. [56] Lawrence RM, Hoeprich PD, Jagdis FA, et al. Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate, Macaca mulatta[J]. J Antimicrob Chemother,1980,6(2):241-249. [57] van Etten EW, Otte-Lambillion M, van Vianen W, et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans[J]. J Antimicrob Chemother,1995,35(4):509-519. |
| [1] | 刘莹婷, 曹励之, 王丹, 杨明华. 两性霉素B 3日加量疗法在急性白血病合并侵袭性真菌病患儿中的临床应用[J]. 中国真菌学杂志, 2021, 16(3): 170-175. |
| [2] | 何沅鸿, 谭清, 杨彤彤, 何盛华, 王印, 周锐峰, 蔡琳. 两性霉素B治疗124例AIDS合并隐球菌脑膜炎的有效性及安全性研究[J]. 中国真菌学杂志, 2019, 14(6): 346-350. |
| [3] | 李英, 秦静, 段彦龙, 黄爽, 赵倩, 赵文, 王莉, 苏雁, 杨菁, 金玲, 王晓玲. 国产两性霉素B漱口治疗儿童血液恶性肿瘤化疗后口腔白斑的安全性和有效性观察[J]. 中国真菌学杂志, 2019, 14(4): 238-239. |
| [4] | 周亚彬, 王千, 张浩, 万喆, 李若瑜, 刘伟. 国产两性霉素B及其他常用抗真菌药物对侵袭性真菌病病原菌的体外抑菌活性研究[J]. 中国真菌学杂志, 2018, 13(5): 277-282. |
| [5] | 崔岩, 李珊山, 侯媛媛, 宋洋, 陈瑞丽, 李洪霞. 球形孢子丝菌黑素抵御抗真菌药物杀伤作用的研究[J]. 中国真菌学杂志, 2018, 13(4): 193-196,212. |
| [6] | 杨敏, 谢霜, 董宇, 杜永洪, 李岱容. 超声联合两性霉素B纳米粒对白念珠菌生物膜杀菌效果评价[J]. 中国真菌学杂志, 2018, 13(3): 134-138. |
| [7] | 刘静, 季海龙, 赵芳, 张睿, 尹凤雷, 曹婷婷, 马洪玉, 许卫星, 王娟. 国产两性霉素B单用或联合其他抗真菌药治疗恶性血液病并真菌感染54例临床分析[J]. 中国真菌学杂志, 2018, 13(2): 83-86,90. |
| [8] | 谢军, 金勤, 吴丹. 复发性外阴阴道念珠菌病45例的临床治疗[J]. 中国真菌学杂志, 2017, 12(3): 152-155. |
| [9] | 王红, 万喆, 余进. 波氏假阿利什霉复合种对4种抗真菌药物的敏感性研究[J]. 中国真菌学杂志, 2015, 10(2): 96-99. |
| [10] | 王学莉, 伏添, 王成立, 胡文能, 张西京. 两性霉素B治疗侵袭性肺部真菌感染的临床分析[J]. 中国真菌学杂志, 2014, 9(3): 163-166. |
| [11] | 赵静, 唐洪辉, 常菲, 肖仕初, 夏照帆. 重度烫伤创面米根霉感染1例[J]. 中国真菌学杂志, 2013, 8(2): 99-100,108. |
| [12] | 张昕, 涂波, 范荣, 聂为民, 赵敏. 鞘内注射两性霉素B治疗隐球菌脑膜炎的META分析[J]. 中国真菌学杂志, 2012, 7(3): 136-141. |
| [13] | 周村建, 王莉, 徐艳, 钟白玉, 郝飞. 多变根毛霉致面部皮肤毛霉病1例[J]. 中国真菌学杂志, 2011, 6(6): 361-362. |
| [14] | 柴俊月, 魏娜, 崔婷婷, 许兰平, 黄晓军. 国产两性霉素B抢先治疗血液病患者肺部侵袭性真菌感染的疗效与安全性分析[J]. 中国真菌学杂志, 2010, 5(3): 144-147. |
| [15] | 王舒, 赵建荣, 杨丹丹. 两性霉素B脂质体致急性胰腺炎1例[J]. 中国真菌学杂志, 2010, 5(3): 178-178,187. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
